Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.44 |
| ▸ | HTR2A | P28223 | 14/20 | 0.44 |
| ▸ | HTR1A | P08908 | 12/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23175425 | 0.89 | DRD2 (0.46) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL12026856 | 0.84 | HIF1A (0.49) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL373467 | 0.81 | BCHE (0.44) | DRD2HTR2AHTR1A | |
| SCHEMBL5995383 | 0.80 | BCHE (0.43) | DRD2HTR2AHTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL1545403 | 0.80 | BCHE (0.43) | DRD2HTR2AHTR1A | |
| SCHEMBL10637150 | 0.79 | DRD2 (0.50) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL10637706 | 0.79 | DRD2 (0.55) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL15033122 | 0.79 | DRD2 (0.48) | DRD2HTR2AHTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL10638213 | 0.78 | DRD2 (0.54) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL2197968 | 0.78 | ACHE (0.62) | DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5532240-A | ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | claimed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | disclosed |
| EP-2183245-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013212-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-5691330-A | ANTIPSYCHOTIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5532240-A | ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | DRD2 6/4885HTR2A 1/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.